Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 8/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.35 |
| ▸ | ACLY | P53396 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alterporriol G/H SCHEMBL15338594 | 1.00 | NFKB1 (0.55) | NFKB1NFKB2RELAIDO1EPHX2 | |
| Alterporriol A/B SCHEMBL30948399 | 0.93 | NFKB1 (0.59) | NFKB1NFKB2RELAIDO1EPHX2 | |
| SCHEMBL29359665 | 0.91 | NFKB1 (0.55) | NFKB1NFKB2RELAEPHX2ELANE | |
| SCHEMBL904371 | 0.88 | NFKB1 (0.59) | NFKB1NFKB2RELAEPHX2ELANE | |
| SCHEMBL13063713 | 0.88 | NFKB1 (0.59) | NFKB1NFKB2RELAEPHX2ELANE | |
| SCHEMBL14923296 | 0.87 | NFKB1 (0.57) | NFKB1NFKB2RELAEPHX2ELANE | |
| SCHEMBL23522374 | 0.86 | NFKB1 (0.59) | NFKB1NFKB2RELAEPHX2ELANE | |
| SCHEMBL29362349 | 0.86 | NFKB1 (0.59) | NFKB1NFKB2RELAEPHX2ELANE | |
| SCHEMBL29360017 | 0.84 | NFKB1 (0.67) | NFKB1NFKB2RELAIDO1PARP1 | |
| SCHEMBL23522462 | 0.84 | NFKB1 (0.67) | NFKB1NFKB2RELAIDO1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435034-B1 | USE OF ANTHRACENE DERIVATIVES AS ANTI-INFECTIVES | SEALIFE PHARMA GMBH (AT) | 2013-10-23 | — | — | EP | claimed |
| US-20120129949-A1 | Use of Anthracene Derivatives as Anti-Infectives | SEALIFE PHARMA GMBH (AT) | 2012-05-24 | — | — | US | claimed |
| EP-2435034-B1 | USE OF ANTHRACENE DERIVATIVES AS ANTI-INFECTIVES | SEALIFE PHARMA GMBH (AT) | 2013-10-23 | — | — | EP | disclosed |
| EP-2435034-B1 | USE OF ANTHRACENE DERIVATIVES AS ANTI-INFECTIVES | SEALIFE PHARMA GMBH (AT) | 2013-10-23 | — | — | EP | disclosed |
| CN-102481272-A | Use of anthracene derivatives as anti-infective agents | SEALIFE PHARMA GMBH | 2012-05-30 | — | — | CN | disclosed |
| US-20120129949-A1 | Use of Anthracene Derivatives as Anti-Infectives | SEALIFE PHARMA GMBH (AT) | 2012-05-24 | — | — | US | disclosed |
| US-20120129949-A1 | Use of Anthracene Derivatives as Anti-Infectives | SEALIFE PHARMA GMBH (AT) | 2012-05-24 | — | — | US | disclosed |
| US-20120129949-A1 | Use of Anthracene Derivatives as Anti-Infectives | SEALIFE PHARMA GMBH (AT) | 2012-05-24 | — | — | US | disclosed |
| EP-2435034-A1 | USE OF ANTHRACENE DERIVATIVES AS ANTI-INFECTIVES | Sealife Pharma GmbH (AT) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010135758-A1 | USE OF ANTHRACENE DERIVATIVES AS ANTI-INFECTIVES | SEALIFE PHARMA GMBH (AT) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010135758-A1 | USE OF ANTHRACENE DERIVATIVES AS ANTI-INFECTIVES | SEALIFE PHARMA GMBH (AT) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129949-A1 | Use of Anthracene Derivatives as Anti-Infectives | ANTXR2, CYP27B1, ANXA11 | NFKB1 1621/4885NFKB2 1867/4885RELA 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.